Clinical trial
Long-Term, Open Label Atomoxetine Study
NCT00190684 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190684 |
|---|---|
| Title | Long-Term, Open Label Atomoxetine Study |
| Official title | Long-Term, Open Label Safety Study of Atomoxetine Hydrochloride in Patients, 6 Years and Older With Attention-Deficit/Hyperactivity Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | atomoxetine |
| Enrollment | 1,553 |
| Start date | Aug 1, 2000 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 17, 2011 |
| Countries | Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Norway, Puerto Rico, South Africa, Sweden and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: